After mounting financial and manufacturing woes, Akorn (AKRX) has filed for bankruptcy protection, a humbling move by a company that was on the verge of being purchased for $4.3 billion just two years ago.

The filing follows a protracted period in which the drug maker haggled with lenders and fended off shareholder lawsuits, which were prompted after Fresenius Kabi walked away from a deal to buy the company. The acquisition fell apart after Fresenius found what it described as “material breaches” in manufacturing standards at Akorn facilities.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • May one observe that “The business has an “underlying strength” makes for an interesting quote. Where exactly do they hide it?

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy